- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02601612
Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Live Recombinant RSV D46cpΔM2-2 Vero Grown Virus Vaccine (Lot RSV #008A), Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Human RSV is the most common viral cause of serious acute lower respiratory illness (LRI) in infants and children under 5 years of age worldwide. This study will evaluate the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegative infants and children. The vaccine will be evaluated in a stepwise fashion beginning in RSV-seropositive children (Group 1), and then in RSV-seronegative infants and children (Group 2). In each group, participants will be randomly assigned to receive a single dose of D46cpΔM2-2 vaccine or placebo at study entry (day 0).
Participants will be enrolled in the study between April 1 and October 31, outside of the RSV season. Group 1 (RSV-seropositive children) will attend several study visits and will be followed for 28 days. Group 2 (RSV-seronegative infants and children) will remain on study until they complete the post-RSV season visit between April 1 and April 30 in the calendar year following enrollment. Participants in Group 2 will also attend several study visits during the time they are enrolled in the study. Study visits for all participants may include clinical assessments, blood collection, and nasal washes.
Type d'étude
Inscription (Anticipé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
RSV-Seropositive Children:
Inclusion Criteria:
- Greater than or equal to 12 months of age and less than 60 months of age
- Received routine immunizations appropriate for age
- Serum RSV neutralizing antibody titer greater than or equal to 1:40
- Serum RSV neutralizing antibody result obtained this calendar year
- Pre-inoculation serum RSV neutralizing antibody specimen obtained less than or equal to 56 days prior to inoculation
- Parent/guardian has completed the study comprehension assessment
- Parent/guardian has signed the study informed consent document (ICD)
- Subject is expected to be available for the duration of the study
Exclusion Criteria:
- Evidence of chronic disease
- Within the past 6 months had a decline in height or weight growth that crosses two major growth percentiles (e.g., from above the 75th to below the 25th)
- Known or suspected impairment of immune function
- Maternal history of positive HIV test
- Bone marrow/solid organ transplant recipient
- Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
- Current or unresolved suspected or documented developmental disorder, delay, or other developmental problem
- Cardiac abnormality requiring treatment
- Lung disease or reactive airway disease
- More than one episode of wheezing in the first year of life
- Wheezing episode or received bronchodilator therapy within the past 12 months
- Previous immunization with an experimental RSV vaccine
- Previous receipt or planned administration of anti-RSV antibody product
- Previous serious vaccine-associated AE or anaphylactic reaction
- Known hypersensitivity to any vaccine component
- Previous receipt of immunoglobulin or any antibody products
- Previous receipt of any other blood products within the past 6 months
- Member of a household that contains an infant who is less than 12 months of age during study days 0 to 10
- Member of a household that includes an immunocompromised individual
- Member of a household that includes a person who has received chemotherapy within the past 12 months
- Will attend a daycare facility that does not separate children by age and contains an infant who is greater than 12 months of age during study days 0 to 10
RSV-Seronegative Infants and Children:
Inclusion Criteria:
- Greater than or equal to 6 months of age and less than 25 months of age
- Received routine immunizations appropriate for age
- Serum RSV neutralizing antibody titer is less than 1:40
- Screening and pre-inoculation serum RSV neutralizing antibody specimen obtained less than or equal to 42 days prior to inoculation
- Parent/guardian has completed the study comprehension assessment
- Parent/guardian has signed the study ICD
- Subject is expected to be available for the duration of the study
- Born at greater than or equal to 37 weeks gestation or is currently greater than 1 year of age
Exclusion Criteria:
- Evidence of chronic disease
- Within the past 6 months had a decline in height or weight growth that crosses two major growth percentiles (e.g., from above the 75th to below the 25th)
- Known or suspected impairment of immune function
- Maternal history of positive HIV test
- Bone marrow/solid organ transplant recipient
- Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
- Current or unresolved suspected or documented developmental disorder, delay, or other developmental problem
- Cardiac abnormality requiring treatment
- Lung disease or reactive airway disease
- More than one episode of wheezing in the first year of life
- Wheezing episode or received bronchodilator therapy within the past 12 months
- Previous immunization with an experimental RSV vaccine
- Previous receipt or planned administration of anti-RSV antibody product
- Previous receipt of immunoglobulin or any antibody products
- Previous receipt of any other blood products within the past 6 months
- Previous serious vaccine-associated AE or anaphylactic reaction
- Known hypersensitivity to any vaccine component
- Member of a household which contains an infant who is less than 6 months of age during study days 0 to 28
- Member of a household that includes an immunocompromised individual
- Member of a household that includes a person who has received chemotherapy within the past 12 months
- Will attend a daycare facility that does not separate children by age and contains an infant who is less than 6 months of age during study days 0 to 28
Temporary Exclusion Criteria for RSV-Seropositive and RSV-Seronegative Children:
To be eligible to participate, RSV-seropositive and RSV-seronegative infants and children must satisfy none of the temporary exclusion criteria. The following conditions are temporary or self-limiting. Once the condition is resolved and the subject is otherwise eligible, the subject may be enrolled or rescreened, if necessary.
Any of the following events at the time of inoculation:
- fever (rectal temperature of greater than or equal to 100.4°F),
- upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis)
- nasal congestion significant enough to interfere with successful inoculation
- otitis media
- Receipt of any killed vaccine or live-attenuated rotavirus vaccine less than 14 days prior to inoculation
Receipt of the following medications less than 28 days prior to inoculation:
- any live vaccine other than rotavirus
- another investigational vaccine or investigational drug,
- systemic corticosteroids administered for greater than 14 days at a dosage equivalent to prednisone at greater than 2 mg/kg or 20 mg daily
- salicylate (aspirin) or salicylate-containing products
Receipt of a non-permitted concomitant medication or any of the following medications less than 3 days prior to inoculation:
- systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis,
- intranasal medications
Scheduled administration of the following in relation to planned inoculation:
- killed vaccine within the 14 days following,
- any live vaccine other than rotavirus within the 28 days following,
- another investigational vaccine or drug within the 28 days following for RSV-seropositive children and the 56 days following for RSV-seronegative infants and children
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Group 1: D46cpΔM2-2 Vaccine
RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
|
Delivered as nose drops
|
Comparateur placebo: Group 1: Placebo
RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
|
Livré sous forme de gouttes nasales
|
Expérimental: Group 2: D46cpΔM2-2 Vaccine
RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
|
Delivered as nose drops
|
Comparateur placebo: Group 2: Placebo
RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
|
Livré sous forme de gouttes nasales
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Frequency of vaccine-related solicited adverse events (AEs) that occur during the acute monitoring phase of the study
Délai: Measured at days 0-10 for seropositive and days 0-28 for seronegative
|
Measured at days 0-10 for seropositive and days 0-28 for seronegative
|
Severity of vaccine-related solicited AEs that occur during the acute monitoring phase of the study
Délai: Measured at days 0-10 for seropositive and days 0-28 for seronegative
|
Measured at days 0-10 for seropositive and days 0-28 for seronegative
|
Frequency of vaccine-related lower respiratory illness
Délai: Measured during study days 0-28 for seropositive subjects and study days 0-56 for seronegative subjects
|
Measured during study days 0-28 for seropositive subjects and study days 0-56 for seronegative subjects
|
Proportion of subjects shedding vaccine virus
Délai: Measured during study days 0-28 for seropositive subjects and study days 0-56 for seronegative subjects
|
Measured during study days 0-28 for seropositive subjects and study days 0-56 for seronegative subjects
|
Proportion of subjects that develop 4-fold or greater increases in RSV neutralizing antibody titer following vaccination
Délai: Measured during study days 0-28 for seropositive subjects and study days 0-56 for seronegative subjects
|
Measured during study days 0-28 for seropositive subjects and study days 0-56 for seronegative subjects
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Ruth A. Karron, MD, Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHSPH)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CIR 308
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infections par le virus respiratoire syncytial
-
Biota Pharma Europe LimitedComplétéInfection par le virus respiratoire syncytial (VRS)Royaume-Uni
-
AbbVie (prior sponsor, Abbott)ComplétéInfection par le virus respiratoire syncytialJapon
-
Shanghai Ark Biopharmaceutical Co., Ltd.Ark Biosciences Pty Ltd.ComplétéINFECTIONS À VIRUS RESPIRATOIRE SYNCYTIALAustralie, Hong Kong, Israël, Liban, Malaisie, Pologne, Taïwan, Turquie
-
PfizerRecrutementInfection par le virus respiratoire syncytialÉtats-Unis, Japon, Chine, Canada
-
Janssen Research & Development, LLCRésiliéVirus respiratoire syncytialÉtats-Unis, Allemagne, Italie, Ukraine, Espagne, Suède, Thaïlande, Argentine, Bulgarie, Japon, Pologne, Canada, Hongrie, Afrique du Sud
-
National Institute of Allergy and Infectious Diseases...ComplétéInfection par le virus respiratoire syncytialÉtats-Unis
-
Gilead SciencesComplétéVirus respiratoire syncytial (VRS)États-Unis, Belgique, Canada, Pays-Bas, Australie, Allemagne, Royaume-Uni, France
-
Gilead SciencesComplétéInfection par le virus respiratoire syncytialCorée, République de, Australie, Israël, Nouvelle-Zélande, Pays-Bas, États-Unis, France, Royaume-Uni, Italie, Belgique, Pologne
-
Sanofi Pasteur, a Sanofi CompanyRecrutementVolontaires en bonne santé | Infection par le virus respiratoire syncytial | Infection à métapneumovirusAustralie, États-Unis
-
AbbVie (prior sponsor, Abbott)Fundasamin (Argentina)ComplétéInfection par le virus respiratoire syncytialArgentine, Chili, Colombie, Equateur, Mexique, Pérou, Uruguay
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
Texas A&M UniversityNutraboltComplétéGlucose and Insulin Response